Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

OPT-CHF phase II study of oxypurinol recommended to continue

July 14, 2004

New phase III study for RSD-1235

July 12, 2004

New data confirm Lovenox is effective antithrombotic for ACS

July 12, 2004

Sponge-derived terpenoids reported by Galileo Laboratories

July 9, 2004

DOV reaches agreement with FDA on clinical trial program for DOV diltiazem

July 9, 2004

Icatibant awarded orphan drug status for edema in severe burn patients

July 9, 2004

Guidant and Miravant to collaborate on cardiovascular PDT development

July 8, 2004

Second clinical trial evaluates trans-NV-04

July 8, 2004

PARG inhibitor effective in vivo in septic shock-like syndrome, PARG may be novel therapeutic target

July 7, 2004

CoTherix submits NDA for Ventavis

July 6, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....